Disorders of the Nervous System

Long-Term Exposure to PFE-360 in the AAV- α -Synuclein Rat Model: Findings and Implications

Michael Aagaard Andersen,^{1,2} Florence Sotty,¹ Poul Henning Jensen,² Lassina Badolo,³ Ross Jeggo,¹ Garrick Paul Smith,⁴ and Kenneth Vielsted Christensen¹

<https://doi.org/10.1523/ENEURO.0453-18.2019>

¹Neurodegeneration, Neuroscience Drug Discovery DK, H. Lundbeck A/S, DK-2500 Valby Denmark, ²Department of Biomedicine, Dandrite, Faculty of Health, Aarhus University, DK-8000 Aarhus Denmark, ³Department of Discovery DMPK, H. Lundbeck A/S, DK-2500 Valby Denmark, and ⁴Department of Discovery Chemistry 2, H. Lundbeck A/S, DK-2500 Valby Denmark

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with impaired motor function and several non-motor symptoms, with no available disease modifying treatment. Intracellular accumulation of pathological α -synuclein inclusions is a hallmark of idiopathic PD, whereas, dominant mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with familial PD that is clinically indistinguishable from idiopathic PD. Recent evidence supports the hypothesis that an increase in LRRK2 kinase activity is associated with the development of not only familial LRRK2 PD, but also idiopathic PD. Previous reports have shown preclinical effects of LRRK2 modulation on α -synuclein-induced neuropathology. Increased subthalamic nucleus (STN) burst firing in preclinical neurotoxin models and PD patients is hypothesized to be causally involved in the development of the motor deficit in PD. To study a potential pathophysiological relationship between α -synuclein pathology and LRRK2 kinase activity in PD, we investigated the effect of chronic LRRK2 inhibition in an AAV- α -synuclein overexpression rat model. In this study, we report that chronic LRRK2 inhibition using PFE-360 only induced a marginal effect on motor function. In addition, the aberrant STN burst firing and associated neurodegenerative processes induced by α -synuclein overexpression model remained unaffected by chronic LRRK2 inhibition. Our findings do not strongly support LRRK2 inhibition for the treatment of PD. Therefore, the reported beneficial effects of LRRK2 inhibition in similar α -synuclein overexpression rodent models must be considered with prudence and additional studies are warranted in alternative α -synuclein-based models.

Key words: AAV- α -synuclein; α -synuclein; LRRK2; Parkinson's disease; PFE-360; subthalamic nucleus

Significance Statement

Mutations in leucine-rich repeat kinase 2 (LRRK2) and α -synuclein are known risk factors for Parkinson's disease (PD). α -Synuclein aggregates at autopsies in both idiopathic and most G2019S cases is suggestive of a common disease pathogenesis. LRRK2 and α -synuclein interaction is hypothesized to play a pivotal role in the pathologic mechanisms. Preclinical *in vivo* evidence of a beneficial effect of LRRK2 inhibition is mixed and limited. This study increases our understanding but underlines the complexity of LRRK2 as a mediator of neuronal dysfunction; importantly, the present findings further outline some of the limitations inherent to the PD model used, and warrant additional preclinical studies in animal models with better relevance to the clinical pathophysiology to draw conclusion on the therapeutic potential of LRRK2 modulation in PD.

Introduction

Historically, neurodegeneration of dopaminergic (DAergic) neurons in substantia nigra pars compacta (SNc) and α -synuclein inclusions in Lewy bodies and Lewy neurites are the histopathological hallmarks of Parkinson's disease (PD; Spillantini et al., 1997; Antony et al., 2013). According to the hypothesis raised by Braak and Beach, pathogenic α -synuclein species may be capable of transmitting their pathologic properties across brain nuclei following neuronal/axonal pathways (Braak et al., 2003, 2004; Beach et al., 2009). A number of known dominant autosomal missense mutations, duplications and triplications in the SNCA gene encoding α -synuclein are risk factors for developing PD (Pankratz et al., 2007; Lill, 2016). The exact physiologic role of α -synuclein is not fully understood. However, virally and genetically manipulated animal models have revealed impairments in synaptic transmission and vesicular machinery (Cabin et al., 2002; Yavich et al., 2004; Watson et al., 2009; Nemani et al., 2010; Busch et al., 2014; Subramaniam et al., 2014), suggesting an involvement of α -synuclein in normal synaptic neurotransmission.

Increased leucine-rich repeat kinase 2 (LRRK2) kinase activity is suggested as the key risk factor associated with late onset PD (Funayama et al., 2002; Paisán-Ruiz et al., 2004; Zimprich et al., 2004a,b; Di Fonzo et al., 2005, 2006; Gilks et al., 2005; Kachergus et al., 2005; Nichols et al., 2005; Healy et al., 2008; Ross et al., 2011). The physiologic function of LRRK2 kinase has recently been assigned as a controller of RAB GTPase activity via increased phosphorylation of several small RAB GTPase, and autophosphorylation (LRRK2-pS1292) of disease relevant mutant LRRK2 (Steger et al., 2016, 2017; Fan et al., 2017; Liu et al., 2017; Thirstrup et al., 2017). Genetic ablation and pharmacological inhibition of LRRK2 have previously been demonstrated to have a promising effect on disease relevant alterations in preclinical *in vivo* models of PD (Lin et al., 2009; Daher et al., 2014, 2015; Andersen et al., 2018a). The partly shared clinical and histopathological manifestation of idiopathic/sporadic and LRRK2 PD is suggestive of at least some shared physiopathological mechanisms between LRRK2 PD and sporadic PD, thereby supporting a potential for LRRK2

inhibition in the modulation of common pathways in the disease mechanisms.

Glutamatergic neurons in the subthalamic nucleus (STN) are a key regulator of neuronal input to the motor thalamus (Nambu et al., 2002). In PD patients and neurotoxin as well as viral models of PD, the loss of striatal DAergic neurotransmission triggers an increase in STN burst discharge pattern, and aberrant oscillations in the beta range throughout the basal ganglia (Brown, 2007; Steigerwald et al., 2008; Wilson et al., 2011; McConnell et al., 2012; Pan et al., 2016; Andersen et al., 2018a). Functional pre-clinical studies and deep brain stimulation studies in both PD models and humans suggest that functional relief of aberrant STN burst firing is associated with acute normalization of motor function (Grill et al., 2004; Benabid et al., 2009; McConnell et al., 2012; Moran et al., 2012; Pan et al., 2016; Wichmann and DeLong, 2016). Recently, acute effects of LRRK2 inhibition have been reported on α -synuclein-induced aberrant STN burst firing (Andersen et al., 2018a), possibly representing a disease relevant measurement to evaluate new disease modulatory targets.

In the present study, AAV- α -synuclein [human wild type (hwt)] overexpression in rat substantia nigra recapitulates PD-like aberrant STN burst firing, DAergic neurodegeneration and motor dysfunction. Using the AAV- α -synuclein overexpression approach, we investigated the effect of chronic LRRK2 inhibition on α -synuclein-induced neuronal dysfunction. Chronic LRRK2 inhibition only had a marginal effect on motor function, which was not associated with any effect on aberrant STN firing, DAergic neurodegeneration measured by striatal tyrosine hydroxylase expression, LRRK2 expression, α -synuclein expression or phosphorylation (α -synuclein-pS129). The present findings do not strongly support the mechanistic link between LRRK2 kinase activity and pathologic α -synuclein, and further reveal some limitations of the preclinical AAV α -synuclein overexpression model.

Materials and Methods

In vivo experimental methods

Ethical statement

All experiments were conducted in accordance with the European Communities Council Directive (86/609/EEC) for the care and use of laboratory animals and the Danish legislation regulating animal experiments.

Animals

Female Sprague Dawley rats were acquired from Taconic Denmark (NTac:SD, $n = 23$ in total). Rats were group housed in humidity (55–65%) and temperature ($22 \pm 1.5^\circ\text{C}$) controlled conditions in a 12/12 h light/dark cycle. Water and food were available *ad libitum*. Female rats were used as experimental subject as they have lower body weight and lower variation in skull size compared to male rats at 26 weeks of age where the experiment was conducted. Lower body weight and variation in skull size are preferred in the *in vivo* electrophysiological experiments.

Received November 19, 2018; accepted October 21, 2019; First published November 4, 2019.

The authors declare no competing financial interests.

Author contributions: M.A.A., F.S., and K.V.C. designed research; M.A.A., L.B., and G.P.S. performed research; M.A.A. analyzed data; M.A.A., F.S., P.H.J., R.J., and K.V.C. wrote the paper.

This work was supported by the by Danish Ministry of Science and Innovation Grant 16448.

Acknowledgements: We thank Camilla Thormod Haugaard and Bo Albrechtsgaard for their expertise and technical assistance.

Correspondence should be addressed to Michael Aagaard Andersen at mian@sund.ku.dk.

<https://doi.org/10.1523/ENEURO.0453-18.2019>

Copyright © 2019 Andersen et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

Viral-mediated α -synuclein overexpression in substantia nigra

Injection of recombinant adeno-associated-viral vectors 2/5 (AAV) was performed in 10- to 12-week-old animals (weighing 250–300 g). Surgical neuroleptic analgesia was induced with a mixture of Hypnorm and Dormicum (corresponding to 157 μ g/kg fentanyl, 2.5 mg/kg midazolam and 5 mg/kg fluanisone). All incisions were infiltrated with local analgesia (lidocaine). The rats were placed in a stereotaxic frame and the body temperature was maintained at 37.5 °C. After a skin incision, a hole was drilled in os parietalis directly above the SNc at the following coordinates, according to Paxinos and Watson (2007): 5.5 mm caudal to bregma and 2.0 mm lateral to the midline. The injection cannula (Hamilton, 30-gauge stainless-steel cannula) was slowly lowered into the injection site located 7.2 mm ventral to the brain surface. A unilateral injection of 3- μ l AAV viral vector (3×10^{10} GC/ml; Vector Biolabs) containing the transgene for hwt α -synuclein or an empty vector (CTRL) was performed at a flow rate of 0.2 μ l/min. The cannula was left in place for 5 min after the injection to allow diffusion. After the skin was sutured, a 24-h analgesic treatment protocol was initiated (buprenorphine 0.05 mg/kg every eight hour). The transgene expression was driven by a chimeric promoter element containing part of the cytomegalovirus promoter and a part of the synthetic chicken β -actin promoter. Further, the expression was enhanced by the woodchuck of hepatitis virus post-translational regulatory element. A successful viral injection was further validated by detection of hwt α -synuclein in the ipsilateral striatum by SDS-PAGE and subsequent Western blotting.

PFE-360 treatment

PFE-360 (Baptista et al., 2015) was synthesized at H. Lundbeck A/S as described in patent application US2014/0005183 (example 217; 1-methyl-4-(4-morpholino-7H-pyrrolo[2,3-d] pyrimidin-5-yl) pyrrole-2-carbonitrile). PFE-360 was dissolved at a concentration of 3 mg/ml in a vehicle containing 10% captisol and adjusted to pH 2 with 1 M methane sulfonic acid. The solution was administered by oral gavage using plastic feeding tubes. Rats receiving PFE-360 were dosed with 7.5 mg/kg twice daily with a 12-h interval. The treatment was initiated on day 1 after AAV injection. The dose of 7.5 mg/kg was chosen based on a separated pharmacokinetic study showing that 7.5 mg/kg gives full LRRK2 kinase inhibition from 1 to 10 h and ~50% LRRK2 kinase inhibition at 12 h after dosing. The plasma pharmacokinetic profile of PFE-360 can be found elsewhere (Andersen et al., 2018b).

Motor symmetry assessment in the cylinder test

Nine weeks after the viral injection, motor function was assessed in the cylinder test. Rats receiving PFE-360 or vehicle were tested 1–2 h after dosing. Briefly, the rat was placed in a transparent cylinder and video recorded for 5 min. A minimum of 15 touches was required to ensure the sensitivity of the test. The ratio between the contralateral forepaw (to the injection) and the total number of touches was used as the primary read out.

Spontaneous locomotor activity

Following the cylinder test, the non-forced spontaneous locomotor activity was evaluated in a cage similar to the home cage with clean bedding but without enrichment for 1 h. Activity was recorded by four photosensors along the cage. There was no habituation period. The activity count was calculated as the number of beam breaks, excluding repeated break of the same beam. Rats receiving PFE-360 or vehicle were tested 5–7 h after dosing.

Single unit recordings of glutamatergic subthalamic neurons

Ten to 12 weeks following the viral vector injection, the same animals were subjected to single unit recording of putative glutamatergic STN neurons under urethane anesthesia (1.6–1.9 g/kg, i.p.). The level of anesthesia was maintained and monitored as absence of the deep pain reflexes but presence of the corneal reflex. This allowed to ensure that recordings were performed under similar levels of anesthesia, as the relative brain state influences the basal ganglia firing properties (Magill et al., 2000). The rat was placed in a stereotaxic frame and the body temperature was maintained at 37.5 $\pm$ 0.5°C. After a midline incision, a hole was drilled in os parietalis above the STN ipsilateral to the viral injection, at the following coordinates: 3.0–4.2 mm caudal to bregma and 2.4–2.8 mm lateral to the midline (Paxinos and Watson, 2007). The brain surface was kept moist with 0.9% saline after removal of the dura mater. The recording electrodes were fabricated from borosilicate glass capillaries (1B150F-4, World Precision Instruments) pulled into a fine tip under heating and broken under a microscope to a tip diameter of 3–8 μ m reaching an *in vitro* resistance of 3–9 M Ω . The electrode was filled with 0.5 M sodium acetate containing 2% of Pontamine Sky Blue. The electrode was slowly lowered into STN using a motorized micromanipulator. STN was typically localized at 6.6–7.8 mm ventral to the brain surface (Paxinos and Watson, 2007). The action potentials were amplified ($\times 10,000$), band pass filtered (300 Hz to 5 kHz), discriminated and monitored on an oscilloscope and an audio monitor. Spike trains of action potentials were captured and analyzed using Spike 2 v 7.13 software with a computer-based system connected to the CED 1401 (Cambridge Electronic Design Ltd.). A minimum of 500 consecutive spikes was used for analysis of basal firing properties. PFE-360 was administered to the rats per oral 1 h before the start of the recording session and ended 6–8 h after dosing.

At end of the recording session, an iontophoretic ejection of Pontamine Sky Blue was achieved by applying a negative voltage to the electrode allowing visualization of the last recording position using classical histologic methods. The recording sites were then retrospectively reconstructed, and neurons were only included in the analysis if the reconstruction provided evidence of the neuron to be within the STN.

Single-unit recordings data analysis

The action potential of glutamatergic neurons in STN is typically short (<2 ms) with a biphasic wave form (Hollerman and Grace, 1992). Each spike-train was carefully

inspected before the analysis using the principle component tools and the overdraw wavemark function in Spike 2 v 7.13, making sure that only spikes from a single neuron were included in the analysis. The signal-to-noise ratio was always $>2:1$. Spike trains were analyzed offline using a custom-made script measuring the firing rate and coefficient of variation of the interspike interval (CV ISI). Briefly, the CV ISI is defined as the ratio between the standard deviation of the ISI and the average ISI $\times 100$ (Herrik et al., 2010). Further, the classification of the neuronal firing pattern was divided into regular, irregular, and bursty based on a visual inspection of the autocorrelogram and the discharge density histogram (Tepper et al., 1995; Kaneoke and Vitek, 1996).

Ex vivo biochemical methods

Brain sampling

At the end of the recording session, the rats were perfused transcardially with 100-ml 0.9% saline containing 0.3% heparin. The brain was removed and sectioned on an ice-cold plate. The striata were snap frozen on dry-ice and stored at -80°C until preparation of tissue lysates for SDS-PAGE and Western blotting. The caudal part of the brain containing STN was stored at -20°C for histologic validation of the recording sites. The cerebellum was weighted and snap frozen in a Covaris tube on dry ice and stored at -80°C until further analysis.

SDS-PAGE and Western blotting sample preparation

Preparation of striatal samples for SDS-PAGE and Western blotting was performed as described previously (Andersen et al., 2018a).

SDS-PAGE and Western blotting quantification of tyrosine hydroxylase, striatal enriched phosphatase, hwt α -synuclein, and phosphorylated α -synuclein-S129

Quantification of TH, STEP and hwt- α -synuclein expression and α -synuclein-S129 phosphorylation were done as described previously (Andersen et al., 2018a; TH: Millipore catalog #AB152, RRID:AB_390204, STEP: LifeSpan catalog #LS-C2901, RRID:AB_2173553, hwt- α -synuclein: Abcam catalog #ab1904, RRID:AB_302666 and α -synuclein-S129 phosphorylation: Abcam catalog #ab51253, RRID:AB_869973). Briefly, the quantification was done using SDS-PAGE and subsequent Western blotting. Finally, the proteins were visualized quantified by infrared detection using Li-Cor Odyssey CLx (Li-COR).

Total LRRK2 and phosphorylated LRRK2-S935 quantification

Total LRRK2 expression levels and the level of LRRK2 inhibition were quantified using SDS-PAGE and subsequent Western blotting as described previously (Andersen et al., 2018b; LRRK2: UC Davis/NIH NeuroMab Facility catalog #73-253, RRID:AB_10671178 and phosphorylated LRRK2-S935: Abcam catalog #ab133450, RRID:AB_2732035). The total LRRK2 was quantified for both ipsilateral and contralateral striatum and reported as the mean of the two measurements.

Quantification of PFE-360 brain exposure

The analysis method is described previously (Andersen et al., 2018a). Briefly, the quantification of PFE-360 brain exposure was performed using a LC-MS/MS coupled to a Waters Acquity UPLC.

Statistical analysis

Neuronal firing properties (firing rate and CV ISI) data were analyzed using Kruskal–Wallis test with Dunn's corrected p value for multiple comparison, as they were non-normally distributed. Distributive differences in firing pattern were statistically assessed using χ^2 analysis. The p value for multiple χ^2 tests were corrected using the Bonferroni correction ($p < 0.0125$ was considered significant). Motor behavior and Western blotting quantifications (TH, STEP, α -synuclein-pS129, LRRK2, and LRRK2-pS935) data were all normally distributed and were analyzed using a one-way ANOVA test with Tukey's *post hoc* multiple comparison. Statistical analysis of human α -synuclein overexpression and unbound PFE-360 exposure were done using an unpaired t test. All statistics and figures were made in GraphPad Prism 7.03. All values are presented as mean $\pm$ SEM.

Results

Chronic PFE-360 dosing modulates AAV- α -synuclein-induced motor deficit

In our effort to evaluate the therapeutic preclinical potential of chronic LRRK2 inhibition, we first tested the effect of PFE-360 (7.5 mg/kg BID) on motor symmetry in the cylinder test. Overall, there was a statistically significant effect on the forepaws ratio across groups (Fig. 1A). Multiple comparisons showed that AAV-overexpression of α -synuclein induced a significant asymmetry in the motor function compared to an empty vector in vehicle-treated animals. Chronic dosing with PFE-360 did not affect the motor symmetry assessed in the cylinder test in animals injected with an empty vector. In rats injected with AAV- α -synuclein, PFE-360 partially normalized the dysfunctional use of forepaws as evidenced by the significantly increased use of the contralateral forepaw compared to vehicle treatment.

Analysis of the spontaneous locomotor activity 5–7 h after the last dosing did not show any overall statistical effect of either the viral vector or the treatment, although a trend for reduced locomotor activity was observed in animals injected with AAV- α -synuclein compared to an empty vector (Fig. 1B).

AAV- α -synuclein-induced aberrant STN burst firing is not attenuated by chronic LRRK2 inhibition using PFE-360

To investigate the modulatory effect of repeated LRRK2 inhibition on STN burst firing induced by hwt α -synuclein overexpression in substantia nigra, rats were repeatedly dosed with PFE-360 for 10–12 weeks following viral injection. The electrophysiological properties of putative glutamatergic neurons in STN were recorded at the end of the treatment period, and 1–8 h following the last dose. A total of 400 putative glutamatergic STN neurons from 22

Figure 1. Chronic PFE-360 treatment slightly normalizes motor function but not STN burst firing induced by AAV- α -synuclein overexpression. **A**, Motor symmetry assessed nine weeks after intracerebral viral inoculation of AAV- α -synuclein or CTRL (empty AAV-vector). The test was performed 1–2 h after dosing (one-way ANOVA, $p < 0.001$; CTRL veh and PFE-360 $N = 6$, α -syn veh and PFE-360 $N = 5$). **B**, Locomotor activity measured 5–7 h after dosing revealed a non-significant trend for a decreased activity in α -synuclein overexpressing rats in both treatment groups compared to CTRL rats. PFE-360 treatment did not have any adverse effect on locomotion in the CTRL group (one-way ANOVA, $p = 0.51$; CTRL veh and PFE-360, $N = 6$, α -syn veh and PFE-360, $N = 5$). **C**, Representative action potential and spike-trains from single unit recordings of putative glutamatergic neuron in the STN. The spike-trains are representative examples of regular (top), irregular (middle), and bursty (bottom) firing patterns. **D**, CV ISI is increased by α -synuclein overexpression in both treatment groups (Kruskal–Wallis test, $p < 0.001$). **E**, Proportional distribution of regular, irregular and bursty neurons ($\chi^2 = 22.28$, $df = 6$, $p = 0.0011$) shows increased proportion of bursty neurons in α -synuclein overexpressing rats in both treatment groups. **F**, The average firing rate of STN neurons is not significantly different between groups (Kruskal–Wallis test, $p = 0.11$). **D–F**, N : number of animals; n : number of neurons; CTRL veh ($N = 5$, $n = 98$), α -synuclein veh ($N = 6$, $n = 99$), CTRL PFE-360 ($N = 6$, $n = 90$), and α -synuclein PFE-360 ($N = 6$, $n = 113$). Tukey’s multiple comparison is represented by the lines; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. For multiple χ^2 tests in (**E**) the Bonferroni-corrected p value was used, * $p < 0.0125$ (four comparisons: significance level, $p = 0.0125$).

rats divided into four groups were included in the final analysis (Fig. 1C–F). Overall, comparison of the STN firing pattern revealed a significant group effect in the distribution of regular, irregular and bursty firing neurons between groups and a significant group effect in the CV ISI (Fig. 1D,E). Multiple comparisons revealed that overexpression of α -synuclein significantly increased the proportion of burst firing neurons and the CV ISI compared to an empty vector in vehicle-treated animals. In empty vector-injected

animals, chronic dosing with PFE-360 7.5 mg/kg BID did not alter the relative distribution of the firing pattern or the CV ISI (CTRL vehicle vs CTRL PFE-360 7.5 mg/kg). In AAV- α -synuclein injected animals, chronic dosing with PFE-360 did not have any significant effect on the relative distribution of the firing pattern or the CV ISI. The CV ISI was significantly increased compared to CTRL PFE-360, to a level comparable to α -syn PFE-360. The relative distribution of firing pattern of α -synuclein was not signif-

Figure 2. Striatal LRRK2 expression is not changed by PFE-360 treatment despite full LRRK2 inhibition. **A**, Western blot analysis of total LRRK2 and phosphorylated LRRK2-Ser935 (LRRK2-pSer935) after 10- to 12-week chronic PFE-360 dosing. The tissues were collected 6–8 h after last dosing. i = ipsilateral to the viral injection; c = contralateral to the viral injection. **B**, Quantification of Western blottings shows that chronic PFE-360 treatment did not affect LRRK2 expression in CTRL rats compared to vehicle treatment. In α-syn rats, PFE-360 treatment significantly lowered LRRK2 expression compared to vehicle treatment, although each α-syn group did not differ significantly from their respective CTRL group (one-way ANOVA, $p = 0.0032$). **C**, The LRRK2-pSer935 to total LRRK2 ratio was used as a measure of target engagement. At full inhibition, the ratio is typically <0.1 and was achieved in both CTRL and α-syn rats treated with PFE-360 (one-way ANOVA, $p < 0.001$). **D**, Unbound PFE-360 brain concentrations 6–8 h after dosing. IC_{50} of PFE-360 was previously calculated to 2.3 nM giving theoretical 99% LRRK2 inhibition at 23 nM (unpaired t test, $p = 0.85$). CTRL veh, CTRL PFE-360 and α-syn veh; $N = 5$, α-syn PFE-360 $N = 6$. Tukey's multiple comparison is represented by the lines; ** $p < 0.01$, *** $p < 0.001$.

icantly altered compared to CTRL PFE-360 or α-synuclein vehicle groups. The firing rate was not overall significant different between groups (Fig. 1*F*).

Striatal LRRK2 expression is not decreased following chronic LRRK2 inhibition

Evaluation of the impact of PFE-360 on total LRRK2 expression levels in striatum revealed an overall significant difference between groups (Fig. 2*A,B*). *Post hoc* analysis revealed no significant effect of AAV-α-synuclein overexpression in vehicle treated rats, nor was there any significant effect of PFE-360 treatment in CTRL rats. However, PFE-360 treatment in AAV-α-synuclein overexpressing rats significantly decreased the LRRK2 expression level compared to vehicle treated α-synuclein overexpressing rats. There was no statistical difference between PFE-360-treated CTRL and α-synuclein rats.

PFE-360 exposure profile and target occupancy in rat brain

LRRK2 engagement and kinase inhibition in striatum of PFE-360 6–8 h after dosing was evaluated using SDS-PAGE and Western blotting (Dzamko et al., 2010, 2012; Nichols et al., 2010). Viral α-synuclein overexpression did

not impact levels of LRRK2-pSer935 or total LRRK2 ratio (Fig. 2*C*). In CTRL and α-synuclein rats dosed with PFE-360 significant decreases in LRRK2-pSer935 to total LRRK2 ratio were observed. The result suggests that extended dosing of PFE-360 at 7.5 mg/kg for 10–12 weeks gives full LRRK2 kinase inhibition 6–8 h after dosing. A single rat exhibiting a PFE-360 exposure level $\sim 3 \times IC_{50}$, suggestive of 70% inhibition at 8 h after dosing, was nevertheless included in the study (Fig. 2*D*). The calculated LRRK2 IC_{50} value and inhibition level is based on a single dose study using 7.5 mg/kg PFE-360 (Andersen et al., 2018a). Based on the exposure levels following a single PFE-360 dose of 7.5 mg/kg, the average level of LRRK2 inhibition in the current study is estimated to be from 100% to 50% over 24 h, fluctuating between 100% at 1–10 h after dosing and 100–50% at 10–12 h after dosing (data shown previously; Andersen et al., 2018a).

LRRK2 inhibition does not attenuate the loss of TH expression in striatum induced by α-synuclein overexpression

Neurodegenerative processes induced by AAV-α-synuclein overexpression were assessed indirectly by quantifying the expression level of TH in striatum. Overall,

Figure 3. Striatal neurodegenerative processes and α -synuclein phosphorylation are not halted by chronic LRRK2 inhibition. **A**, Western blot analysis of tyrosine hydroxylase (TH) and hwt α -synuclein (hwt α -syn; left) as well as phosphorylation of α -synuclein-S129 (α -syn pS129; right). i = ipsilateral to the viral injection; c = contralateral to the viral injection. **B**, Quantification of TH expression from ipsilateral and contralateral striatum normalized to STEP46 and presented as percentage of contralateral striatum shows a significant loss of TH expression in α -syn overexpressing rats in both treatment groups (one-way ANOVA, $p < 0.001$). **C**, The expression level of hwt α -synuclein normalized to STEP46 is not significantly different between groups (unpaired t test, $p = 0.22$). **D**, The α -synuclein-S129 phosphorylation from ipsilateral and contralateral striatum normalized to STEP46 and presented as percentage of contralateral striatum is not significantly different between groups (one-way ANOVA, $p = 0.076$). CTRL veh, CTRL PFE-360 and α -syn veh; $N = 5$, α -syn PFE-360 $N = 6$. Tukey's multiple comparison is represented by the lines; *** $p < 0.001$.

there was a significant effect of groups on striatal TH expression levels (Fig. 3A,B). *Post hoc* analysis revealed a significant loss of striatal TH induced by AAV- α -synuclein overexpression compared to an empty vector independently of treatment.

LRRK2 inhibition does not affect human wt α -synuclein expression or phosphorylation of total α -synuclein

The overexpression of hwt α -synuclein was not significantly different between PFE-360 and vehicle-treated animals (Fig. 3A,C). The levels of pS129- α -synuclein in the striatum were overall not significantly different across groups (Fig. 3A,D). A trend for increased expression was observed following AAV- α -synuclein overexpression compared to CTRL animals although this was not significant. Chronic LRRK2 inhibition with PFE-360 did not impact α -synuclein-pS129 levels compared to vehicle in CTRL or AAV- α -synuclein rats.

Discussion

Firstly, the findings suggest that the use of our current preclinical PD model in terms of predicting LRRK2 inhibitor efficacy in the clinic should be highly cautioned. Secondly, further investigation into mechanisms underlying these differences between models and investigators is needed before any solid conclusions can be made on the

translational value of our current preclinical PD model. Finally, the discrepancy between the reported acute and present chronic effects of LRRK2 inhibition on aberrant α -synuclein-induced STN firing activity represents an interesting aspect of LRRK2 as a regulator of basal ganglia neurotransmission. Previous reports using acute or chronic LRRK2 inhibition have shown preclinical modulatory and protective effects of LRRK2 inhibition in α -synuclein-based PD models, supporting a pathophysiological interaction between LRRK2 kinase function and α -synuclein-induced pathology (Lin et al., 2009; Daher et al., 2015; Andersen et al., 2018a). In the present report, chronic LRRK2 inhibition had a marginal restorative effect on the motor performance evaluated in the cylinder test. The apparent PFE-360-induced improvement in motor function was not correlated to a similar reversal of STN burst firing. It should however be noted that the evaluation of forepaw use typically requires larger group size than used in the present study. The main aim of the cylinder test was to evaluate the efficiency of α -synuclein overexpression, which was indeed achieved as indicated by the strong motor asymmetry. Unfortunately, the small group size did not allow to make a definite conclusion on the effect of PFE-360 due to the minor level of significance of the reversal. In the event of an actual effect of PFE-360 on motor function, this would suggest that chronic LRRK2

inhibition may exert effects on motor function through action on other pathways bypassing STN, e.g., affecting neurotransmission and/or synaptic plasticity within the motor circuit, thereby functionally circumventing the relative strength/importance of STN firing on the motor output. The complexity of the motor circuit, where both strength and timing of a signal through the four pathways in the basal ganglia are important in determining the motor outcome (Nambu et al., 2002; Mastro and Gittis, 2015), may contribute to the possible discrepancy between the effects of PFE-360 on motor behavior and STN activity. Changes in synaptic plasticity have been reported in transgenic animals overexpressing LRRK2 (Beccano-Kelly et al., 2015; Sweet et al., 2015), but no data from LRRK2 knock-out animals is available. In the latter, it is conceivable that LRRK2 ablation from conception may induce compensatory mechanisms which would not be observed in wild-type animals unless long-term pharmacological inhibition would trigger similar compensations. Another possibility is that the function of LRRK2 inhibition needs an external trigger to reveal its functional involvement in neurotransmission such as impaired DAergic neurotransmission in substantia nigra and striatum. In this respect, alterations in glutamatergic transmission in striatal slices from G2019S-LRRK2 transgenic animals were only observed when rotenone, a mitochondrial toxin, was also present, indicating that LRRK2 might only play a role in the diseased state, such as impaired DAergic neurotransmission (Tozzi et al., 2018). In support, recent studies have suggested that LRRK2 kinase activity is increased in substantia nigra in the AAV- α -synuclein overexpression model and in rotenone models as well as in postmortem tissue from idiopathic PD patients (Howlett et al., 2017; Di Maio et al., 2018).

The acute LRRK2 inhibition with PFE-360 was shown to drastically reduce the spontaneous locomotor activity of control animals (Andersen et al., 2018a), a hypolocomotor effect was not observed after repeated PFE-360 treatment in the present study. This potentially indicates an adaptation to the hypolocomotor effect after repeated administration. Our target engagement measurements showed full LRRK2 inhibition in the brain after repeated treatment (and periphery; data not shown; Andersen et al., 2018b), but no consistent change in LRRK2 expression, thereby ruling out adaptive effects mediated directly by LRRK2 and further suggesting the existence of adaptive mechanisms taking place downstream of LRRK2. Further investigation in long-term treated subjects preclinically and clinically will be needed to validate such physiologic effects.

Our investigation recapitulated the effect of AAV- α -synuclein overexpression on STN basal firing properties by increasing the proportion of burst firing neurons, mimicking findings in neurotoxin models and PD patients (Hollerman and Grace, 1992; Bergman et al., 1994; Ni et al., 2000; Iancu et al., 2005; Brazhnik et al., 2014; Pan et al., 2016). As above mentioned, chronic LRRK2 inhibition using PFE-360 was unable to counteract AAV- α -synuclein-induced aberrant STN burst firing. Previously, aberrant STN firing in the AAV- α -synuclein rat model is

reported to be normalized by acute LRRK2 inhibition using PFE-360 (Andersen et al., 2018a). In the present study, all putative STN neurons were recorded under 70–100% LRRK2 inhibition (based on theoretical back calculations of brain exposure over time; data not shown). The discrepancy between the effect of acute and chronic LRRK2 inhibition on STN firing properties further supports induction of downstream adaptation to PFE-360 after long-term exposure, which was also observed in the locomotor test. Recent investigation has functionally linked LRRK2 activation of RAB35 GTPase to the propagation of α -synuclein pathology, together with a number of other RAB GTPases (e.g., Rab3A/B/C/D, Rab8A/B, Rab10, Rab12, Rab29, Rab35, and Rab43; Beilina et al., 2014; Steger et al., 2016; Alessi and Sammler, 2018; Bae et al., 2018). The functional diversity of the RAB GTPase family highly complicates the relationship between LRRK2 inhibition, STN firing pattern and motor function. The involvement of RAB GTPases in cellular trafficking puts the regulatory potential of LRRK2 on neurotransmission in a vulnerable position, in modulating both pathogenesis and synaptic function. A shift in the membrane-cytosol RAB GTPase homeostasis caused by chronic LRRK2 inhibition has the potential to alter intracellular trafficking (Steger et al., 2016). This in turn may indirectly modulate neurotransmission both presynaptically and postsynaptically, e.g., by interfering with neurotransmitter release and/or reuptake and changing ion-channel membrane density, as described in other tissues as well as in neurons (Farinha and Matos, 2018; Mignogna and D'Adamo, 2018). In this perspective, reversal of the PD-like motor phenotype might take place at any place in motor related nuclei downstream of STN. Substantia nigra pars reticulata receives glutamatergic input from STN and is the main output from the basal ganglia sending projections to the mesencephalic locomotor region (MLR) in the mid-brain. Direct unilateral activation of MLR can evoke bilateral locomotor behavior (Caggiano et al., 2018), a regulation of synaptic function at this level have the potential modulate motor output.

We further showed that chronic treatment with PFE-360 did not have any impact on DAergic neurodegenerative processes, striatal hwt- α -synuclein expression or striatal α -synuclein-pS129 level induced by AAV- α -synuclein overexpression in substantia nigra and associated pathways. The level of Striatal TH expression is previously shown to correlate well with the level of neurodegeneration in SNc (Oliveras-Salv et al., 2013). The findings contrast findings by Daher et al. (2015) who reported protection of DAergic neurons from α -synuclein-induced neurodegeneration after chronic treatment with a similar LRRK2 inhibitor chemotype (Daher et al., 2015). A possible explanation for this discrepancy is related to the different design of the respective studies. In the study by Daher et al. (2015), animals were assessed four weeks following viral injection and drug treatment initiation, which may have allowed revealing a delay in the progression of the pathology. The viral serotype used was also different in their study compared to the present, which can have important impact on the infectious potential of

the viral vector (Van der Perren et al., 2011). Importantly, the treatment regimen used in our study did not result in full LRRK2 inhibition throughout the whole duration of the treatment based on the free brain concentration of PFE-360 at 12 h after dose (data from acute administration of PFE-360; Andersen et al., 2018a). Whether full brain LRRK2 inhibition was achieved throughout the study reported by Daher et al. (2015) is unknown. Thus, to fully explore the potential of LRRK2 kinase inhibitors in pre-clinical models, further development of novel LRRK2 inhibitors with more optimal pharmacokinetic and pharmacodynamic properties is needed or a study design reaching full LRRK2 inhibition 24 h/d. An alternative explanation for the lack of LRRK2 kinase inhibitor effects could relate to the expression pattern of LRRK2 in rats. A recent study has shown that the LRRK2 expression is undetectable in DAergic neurons (West et al., 2014), excluding direct interaction between LRRK2 and α -synuclein in our study. Endogenous LRRK2 in rats is mainly localized to cortico-striatal neurons and MSNs (Davies et al., 2013; West et al., 2014).

In the literature it has consistently been observed that other kinases than LRRK2 phosphorylate the Ser935 site but only if ATP is bound in the catalytic domain and LRRK2 attains an active conformation (Dzambo et al., 2010, 2012; Nichols et al., 2010). Thus, we used the phosphorylation of Ser935-LRRK2 as a surrogate marker of target engagement and full target engagement of LRRK2 is also equivalent with full LRRK2 inhibition and loss of LRRK2 enzymatic activity. It is further shown that the IC₅₀ value for LRRK2 inhibition with PFE-360 is the same for pThr73-Rab10 as the IC₅₀ for LRRK2 inhibition on pSer935-LRRK2 (Thirstrup et al., 2017).

Chronic treatment with PFE-360 in CTRL rats was not associated with a change in LRRK2 expression in the striatum *in vivo*. Although LRRK2 expression was significantly lower in rats overexpressing α -synuclein treated with PFE-360 compared to vehicle, α -synuclein overexpression in vehicle-treated rats was not associated to any significant change in LRRK2 expression compared to Ctrl rats. The apparent difference in LRRK2 expression between PFE-360- and vehicle-treated α -synuclein overexpressing rats may therefore result from methodological variation rather than a pathophysiological effect. Previous studies in the AAV- α -synuclein rat model have not found similar effects of α -synuclein overexpression on LRRK2 expression (Andersen et al., 2018a). The lack of changes in LRRK2 expression after chronic LRRK2 inhibition in CTRL rats is in agreement with similar findings in the brain after 11 d of chronic treatment with MLI-2 (Fell et al., 2015). In contrast, others have reported large decreases in total brain LRRK2 expression *in vivo* and *in vitro* in cellular systems after LRRK2 kinase inhibition (Herzig et al., 2011; Daher et al., 2015; Fuji et al., 2015; Zhao et al., 2015; Lobbastael et al., 2016). In this regard, the species (rat vs mouse vs non-human primate) and LRRK2 expression level should be considered. *In vitro* overexpression of LRRK2 might be very different from *in vivo* conditions with much lower expression of LRRK2 *in vivo* and might rep-

resent different mechanisms not allowing direct comparison.

Although the viral overexpression model has considerably increased our understanding of α -synuclein-induced alterations in the basal ganglia circuitry, the α -synuclein preformed fibrils model has been recently suggested to represent a more faithful model of idiopathic PD (Duffy et al., 2018), and may therefore be highly valuable to further validate LRRK2 as a therapeutic target for idiopathic PD.

Summary

We have demonstrated that chronic LRRK2 inhibition induced a marginal reversal of the motor dysfunction in the AAV- α -synuclein rat model of PD. This effect was not associated with any beneficial effect on STN burst firing or loss of striatal TH expression. The discrepancies between previously reported acute effects and the present chronic effects of LRRK2 inhibition may be dependent on compensatory mechanisms after chronic LRRK2 inhibition, or on the limited validity of the AAV overexpression model as a PD model. Further studies in other preclinical models such as the α -synuclein PFF model may prove valuable.

In the search for the precise mechanisms underlying a putative interaction between LRRK2 and α -synuclein, changes in synaptic plasticity and vesicular trafficking seems to play a pivotal role in model systems manipulating neuronal and non-neuronal LRRK2 kinase function, respectively. Such changes might result in wanted or unwanted effects. It was previously described that LRRK2 is involved in synaptic plasticity and that it is dysregulated in the parkinsonian state (Beccano-Kelly et al., 2015; Chu et al., 2015; Mastro and Gittis, 2015; Sweet et al., 2015), thereby strengthening a potential beneficial effect of LRRK2 inhibition on synaptic plasticity in the pathologic conditions.

References

- Alessi DR, Sammler E (2018) LRRK2 kinase in Parkinson's disease. *Science* 360:36–37.
- Andersen MA, Christensen KV, Badolo L, Smith GP, Jeggo R, Jensen PH, Andersen KJ, Sotty F (2018a) Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV- α -synuclein is normalized by LRRK2 modulation. *Neurobiol Dis* 116:13–27.
- Andersen MA, Wegener KM, Larsen S, Badolo L, Smith GP, Jeggo R, Jensen PH, Sotty F, Christensen KV, Thougard A (2018b) PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. *Toxicology* 395:15–22.
- Antony PMA, Diederich NJ, Krüger R, Balling R (2013) The hallmarks of Parkinson's disease. *FEBS J* 280:5981–5993.
- Bae EJ, Kim DK, Kim C, Mante M, Adame A, Rockenstein E, Ulusoy A, Klinkenberg M, Jeong GR, Bae JR, Lee C, Lee HJ, Lee BD, Di Monte DA, Masliah E, Lee SJ (2018) LRRK2 kinase regulates α -synuclein propagation via RAB35 phosphorylation. *Nat Commun* 9:3465.
- Baptista MAS, Merchant KM, Bhargava S, Bryce D, Ellis M, Estrada AA, Fell M, Fuji RN, Galatsis P, Hill S, Hirst WD, Houle C, Kennedy M, Liu X, Maddess M, Markgraf C, Mei H, Needle E, Steyn S, Yi Z, et al. (2015) LRRK2 kinase inhibitors of different structural classes induce abnormal accumulation of lamellar bodies in type II pneumocytes in non-human primates but are reversible and without pulmonary functional consequences. Available at <https://>

- www.michaeljfox.org/publication/lrrk2-kinase-inhibitors-different-structural-classes-induce-abnormal-accumulation.
- Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG; Arizona Parkinson's Disease Consortium (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. *Acta Neuropathol* 117:613–634.
- Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, Chou P, Cao L-P, Bergeron S, Mitchell E, Han H, Melrose HL, Tapia L, Raymond LA, Farrer MJ, Milnerwood AJ (2015) LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. *Hum Mol Genet* 24:1336–1349.
- Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA; International Parkinson's Disease Genomics Consortium; North American Brain Expression Consortium; Olszewski M, Hauser DN, Kumaran R, Lozano AM, Baekelandt V, Greene LE, et al. (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. *Proc Natl Acad Sci USA* 111:2626–2631.
- Benabid AL, Chabardes S, Mitrofanis J, Pollak P (2009) Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. *Lancet Neurol* 8:67–81.
- Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. *J Neurophysiol* 72:507–520.
- Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 24:197–211.
- Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. *Cell Tissue Res* 318:121–134.
- Brazhnik E, Novikov N, McCoy AJ, Cruz AV, Walters JR (2014) Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats. *Exp Neurol* 261:563–577.
- Brown P (2007) Abnormal oscillatory synchronisation in the motor system leads to impaired movement. *Curr Opin Neurobiol* 17:656–664.
- Busch DJ, Oliphant PA, Walsh RB, Banks SML, Woods WS, George JM, Morgan JR (2014) Acute increase of α -synuclein inhibits synaptic vesicle recycling evoked during intense stimulation. *Mol Biol Cell* 25:3926–3941.
- Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. *J Neurosci* 22:8797–8807.
- Caggiano V, Leiras R, Goñi-Erro H, Masini D, Bellardita C, Bouvier J, Caldeira V, Fisone G, Kiehn O (2018) Midbrain circuits that set locomotor speed and gait selection. *Nature* 553:455–460.
- Chu HY, Atherton JF, Wokosin D, Surmeier DJ, Bevan MD (2015) Heterosynaptic regulation of external globus pallidus inputs to the subthalamic nucleus by the motor cortex. *Neuron* 85:364–376.
- Daher JPL, Volpicelli-Daley L, a, Blackburn JP, Moehle MS, West AB (2014) Abrogation of α -synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. *Proc Natl Acad Sci USA* 111:9289–9294.
- Daher JPL, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y, Steyn SJ, Galatsis P, Hirst WD, West AB (2015) Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α -synuclein gene-induced neurodegeneration. *J Biol Chem* 290:19433–19444.
- Davies P, Hinkle KM, Sukar NN, Sepulveda B, Mesias R, Serrano G, Alessi DR, Beach TG, Benson DL, White CL, Cowell RM, Das SS, West AB, Melrose HL (2013) Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. *Biochem J* 453:101–113.
- Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore N, Goldwurm S, Breedveld G, Sampaio C, Meco G, Barbosa E, Oostra BA, Bonifati V (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. *Lancet* 365:412–415.
- Di Fonzo A, Wu-Chou YH, Lu C-S, van Doeselaar M, Simons EJ, Rohé CF, Chang H-C, Chen R-S, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. *Neurogenetics* 7:133–138.
- Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, Zharikov A, Van Laar A, Stepan AF, Lanz TA, Kofler JK, Burton EA, Alessi DR, Hastings TG, Greenamyre JT (2018) LRRK2 activation in idiopathic Parkinson's disease. *Sci Transl Med* 10:eaar5429.
- Duffy MF, Collier TJ, Patterson JR, Kemp CJ, Fischer DL, Stoll AC, Sortwell CE (2018) Quality over quantity: advantages of using alpha-synuclein preformed fibril triggered synucleinopathy to model idiopathic Parkinson's disease. *Front Neurosci* 12:621.
- Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. *Biochem J* 430:405–413.
- Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, Tan L, Choi H, Gray N, Cohen P, Pedrioli P, Clark K, Alessi DR (2012) The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during toll-like receptor signaling. *PLoS One* 7:e39132.
- Fan Y, Howden AJ, Sarhan AR, Lis P, Ito G, Martinez TN, Brockmann K, Gasser T, Alessi DR, Sammler EM (2017) Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. *Biochem J* 475:23–44.
- Farinha CM, Matos P (2018) Rab GTPases regulate the trafficking of channels and transporters – a focus on cystic fibrosis. *Small GTPases* 9:136–144.
- Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H, Miller M, Poulet FM, Scott JD, Smith MD, Yin Z, Zhou X, Parker EM, Kennedy ME, Morrow JA (2015) MLI-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. *J Pharmacol Exp Ther* 355:397–409.
- Fuji RN, Flagella M, Baca M, Baptista MA, Brodbeck J, Chan BK, Fiske BK, Honigberg L, Jubb AM, Katavolos P, Lee DW, Lewin-Koh SC, Lin T, Liu X, Liu S, Lyssikatos JP, O'Mahony J, Reichelt M, Roose-Girma M, Sheng Z, et al. (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. *Sci Transl Med* 7:273ra15.
- Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. *Ann Neurol* 51:296–301.
- Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. *Lancet* 365:415–416.
- Grill WM, Snyder AN, Miocinovic S (2004) Deep brain stimulation creates an informational lesion of the stimulated nucleus. *Neuroreport* 15:1137–1140.
- Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol* 7:583–590.
- Herrik KF, Christophersen P, Shepard PD (2010) Pharmacological modulation of the gating properties of small conductance Ca^{2+} -activated K^{+} channels alters the firing pattern of dopamine neurons in vivo. *J Neurophysiol* 104:1726–1735.
- Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ, Schmid P, Danner S, Schnell CR, Müller M, Kinzel B, Grevot A, Bolognani F, Stirn M, Kuhn RR,

- Kaupmann K, van der Putten PH, Rovelli G, et al. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. *Hum Mol Genet* 20:4209–4223.
- Hollerman JR, Grace AA (1992) Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol. *Brain Res* 590:291–299.
- Howlett EH, Jensen N, Belmonte F, Zafar F, Hu X, Kluss J, Schüle B, Kaufman BA, Greenamyre JT, Sanders LH (2017) LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease. *Hum Mol Genet* 26:4340–4351.
- Iancu R, Mohapel P, Brundin P, Paul G (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. *Behav Brain Res* 162:1–10.
- Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czystewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. *Am J Hum Genet* 76:672–680.
- Kaneoke Y, Vitek JL (1996) Burst and oscillation as disparate neuronal properties. *J Neurosci Methods* 68:211–223.
- Lill CM (2016) Genetics of Parkinson's disease. *Mol Cell Probes* 30:386–396.
- Lin X, Parisiadou L, Gu X-L, Wang L, Shim H, Sun L, Xie C, Long C-X, Yang W-J, Ding J, Chen ZZ, Gallant PE, Tao-Cheng J-H, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. *Neuron* 64:807–827.
- Liu Z, Bryant N, Kumaran R, Beilina A, Abeliovich A, Cookson MR, West AB (2017) LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. *Hum Mol Genet* 27:385–395.
- Lobbestael E, Civiero L, De Wit T, Taymans J-M, Greggio E, Baekelandt V (2016) Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation. *Sci Rep* 6:33897.
- Magill PJ, Bolam JP, Bevan MD (2000) Relationship of activity in the subthalamic nucleus–globus pallidus network to cortical electroencephalogram. *J Neurosci* 20:820–833.
- Mastro KJ, Gittis AH (2015) Striking the right balance: cortical modulation of the subthalamic nucleus–globus pallidus circuit. *Neuron* 85:233–235.
- McConnell GC, So RQ, Hilliard JD, Lopomo P, Grill WM (2012) Effective deep brain stimulation suppresses low-frequency network oscillations in the basal ganglia by regularizing neural firing patterns. *J Neurosci* 32:15657–15668.
- Mignogna ML, D'Adamo P (2018) Critical importance of RAB proteins for synaptic function. *Small GTPases* 9:145–157.
- Moran A, Stein E, Tischler H, Bar-Gad I (2012) Decoupling neuronal oscillations during subthalamic nucleus stimulation in the parkinsonian primate. *Neurobiol Dis* 45:583–590.
- Nambu A, Tokuno H, Takada M (2002) Functional significance of the cortico–subthalamo–pallidal 'hyperdirect' pathway. *Neurosci Res* 43:111–117.
- Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle recluster after endocytosis. *Neuron* 65:66–79.
- Ni Z, Bouali-Benazzouz R, Gao D, Benabid AL, Benazzouz A (2000) Changes in the firing pattern of globus pallidus neurons after the degeneration of nigrostriatal pathway are mediated by the subthalamic nucleus in the rat. *Eur J Neurosci* 12:4338–4344.
- Nichols RJ, Dзамко N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. *Biochem J* 430:393–404.
- Nichols WC, Pankratz N, Hernandez D, Paisán-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. *Lancet* 365:410–412.
- Oliveras-Salvá M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D'Hooge R, Van den Haute C, Baekelandt V (2013) rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. *Mol Neurodegener* 8:44.
- Paisán-Ruiz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Martí Carrera I, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* 44:595–600.
- Pan MK, Kuo SH, Tai CH, Liou JY, Pei JC, Chang CY, Wang YM, Liu WC, Wang TR, Lai WS, Kuo CC (2016) Neuronal firing patterns outweigh circuitry oscillations in parkinsonian motor control. *J Clin Invest* 126:4516–4526.
- Pankratz N, Pankratz N, Foroud T, Foroud T (2007) Genetics of Parkinson disease. *Genet Med* 9:801–811.
- Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. San Diego: Elsevier.
- Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, et al. (2011) Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. *Lancet Neurol* 10:898–908.
- Spillantini MG, Schmidt ML, Lee VY, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. *Nature* 388:839–840.
- Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Wachter S, Lorentzen E, Duddy G, Wilson S, Baptista MA, Fiske BK, Fell MJ, Morrow JA, Reith AD, Alessi DR, Mann M (2016) Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. *Elife* 5:e12813.
- Steger M, Diez F, Dhekne HS, Lis P, Nirujogi RS, Karayel O, Tonelli F, Martinez TN, Lorentzen E, Pfeffer SR, Alessi DR, Mann M (2017) Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. *Elife* 6:e31012.
- Steigerwald F, Pötter M, Herzog J, Pinsker M, Kopper F, Mehdorn H, Deuschl G, Volkman J (2008) Neuronal activity of the human subthalamic nucleus in the parkinsonian and nonparkinsonian state. *J Neurophysiol* 100:2515–2524.
- Subramaniam M, Althof D, Gispert S, Schwenk J, Auburger G, Kulik A, Fakler B, Roeper J (2014) Mutant α -synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels. *J Neurosci* 34:13586–13599.
- Sweet ES, Saunier-Rebori B, Yue Z, Blitzer RD (2015) The Parkinson's disease-associated mutation LRRK2-G2019S impairs synaptic plasticity in mouse hippocampus. *J Neurosci* 35:11190–11195.
- Tepper JM, Martin LP, Anderson DR (1995) GABAA receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projection neurons. *J Neurosci* 15:3092–3103.
- Thirstrup K, Dächsel JC, Oppermann FS, Williamson DS, Smith GP, Fog K, Christensen KV (2017) Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. *Sci Rep* 7:10300.
- Tozzi A, Tantucci M, Marchi S, Mazzocchetti P, Morari M, Pinton P, Mancini A, Calabresi P (2018) Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease. *Cell Death Dis* 9:204.

- Van der Perren A, Toelen J, Carlon M, Van den Haute C, Coun F, Heeman B, Reumers V, Vandenberghe LH, Wilson JM, Debyser Z, Baekelandt V (2011) Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. *Gene Ther* 18:517–527.
- Watson JB, Hatami A, David H, Masliah E, Roberts K, Evans CE, Levine MS (2009) Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. *Neuroscience* 159:501–513.
- West AB, Cowell RM, Daher JPL, Moehle MS, Hinkle KM, Melrose HL, Standaert DG, Volpicelli-Daley LA (2014) Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. *J Comp Neurol* 522:2465–2480.
- Wichmann T, DeLong MR (2016) Deep brain stimulation for movement disorders of basal ganglia origin: restoring function or functionality? *Neurotherapeutics* 13:264–283.
- Wilson CJ, Beverlin B, Netoff T (2011) Chaotic desynchronization as the therapeutic mechanism of deep brain stimulation. *Front Syst Neurosci* 5:50.
- Yavich L, Tanila H, Vepsäläinen S, Jäkälä P (2004) Role of alpha-synuclein in presynaptic dopamine recruitment. *J Neurosci* 24:11165–11170.
- Zhao J, Molitor TP, Langston JW, Nichols RJ (2015) LRRK2 dephosphorylation increases its ubiquitination. *Biochem J* 469:107–120.
- Zimprich A, Müller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M, Lockhart P, Strongosky A, Kachergus J, Calne DB, Stoessl J, Uitti RJ, Pfeiffer RF, Trenkwalder C, Homann N, Ott E, Wenzel K, Asmus F, Hardy J, Wszolek Z, Gasser T (2004a) The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. *Am J Hum Genet* 74:11–19.
- Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, et al. (2004b) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* 44:601–607.